GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shire PLC (NAS:SHPG) » Definitions » Return-on-Tangible-Equity

Shire (SHPG) Return-on-Tangible-Equity : Negative Tangible Equity% (As of Sep. 2018)


View and export this data going back to 1998. Start your Free Trial

What is Shire Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Shire's annualized net income for the quarter that ended in Sep. 2018 was $2,149 Mil. Shire's average shareholder tangible equity for the quarter that ended in Sep. 2018 was $-11,912 Mil. Therefore, Shire's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2018 was Negative Tangible Equity%.

The historical rank and industry rank for Shire's Return-on-Tangible-Equity or its related term are showing as below:

SHPG's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -48.13
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Shire Return-on-Tangible-Equity Historical Data

The historical data trend for Shire's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shire Return-on-Tangible-Equity Chart

Shire Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.50 184.96 Negative Tangible Equity Negative Tangible Equity Negative Tangible Equity

Shire Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Negative Tangible Equity Negative Tangible Equity Negative Tangible Equity Negative Tangible Equity Negative Tangible Equity

Competitive Comparison of Shire's Return-on-Tangible-Equity

For the Biotechnology subindustry, Shire's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shire's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shire's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Shire's Return-on-Tangible-Equity falls into.



Shire Return-on-Tangible-Equity Calculation

Shire's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2017 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2017 )  (A: Dec. 2016 )(A: Dec. 2017 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2017 )  (A: Dec. 2016 )(A: Dec. 2017 )
=4271.5/( (-23637.7+-16701.4 )/ 2 )
=4271.5/-20169.55
=Negative Tangible Equity %

Shire's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2018 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Sep. 2018 )  (Q: Jun. 2018 )(Q: Sep. 2018 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Sep. 2018 )  (Q: Jun. 2018 )(Q: Sep. 2018 )
=2148.8/( (-12393.8+-11430.2)/ 2 )
=2148.8/-11912
=Negative Tangible Equity %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2018) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Shire  (NAS:SHPG) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Shire Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Shire's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Shire (SHPG) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005, which established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007, which brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.
Executives
James H Cavanaugh director 265 HOTHORPE LANE, VILLANOVA PA 19085

Shire (SHPG) Headlines

From GuruFocus

Chris Davis' Top 3 Buys of the 1st Quarter

By James Li James Li 05-14-2018